SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

CEO Angelos Stergious 15th-anniversary post highlighting GPS and SLS009 has fueled bullish interpretations and speculation about a potential buyout, though no deal is confirmed. The main debate centers on the REGAL Phase 3 trials final analysis: traders view the wait for the 80-event trigger as a possible sign of prolonged survival, while skeptics stress the uncertain, binary clinical outcome.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst is drawing attention for continued share-price weakness despite growing ORLADEYO sales and raised revenue guidance. Traders are divided between seeing the profitable business and pipeline as undervalued and doubting managements acquisition-led strategy, with sentiment hinging on future navenibart and Netherton data amid HAE competition.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows dominates discussion, with traders linking the weakness to deteriorating sentiment around Trump ahead of the midterms and the companys limited operating performance; bearish views prevail, though some see potential for a short-term bounce.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as Middle East conflict and reported attacks on shipping and energy infrastructure fuel concerns about oil supply disruptions. Traders are split between betting that those risks will keep oil elevated and expecting peace-deal headlines or a normalization of flows to unwind the risk premium, contributing to sharp swings.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics sharp rally is tied to its agreement to sell its Prenatal Health testing business to Labcorp for cash, which traders view as a strategic reshaping that could strengthen the balance sheet. The reaction is divided: bulls cite the deal and heavy-volume momentum, while skeptics argue the divested unit was an important revenue source and worry about the remaining business and debt.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas planned public listing of its Monee financial-services arm and launch of an AI enterprise platform are driving the discussion as shares sell off. Traders worry that a separation could weaken the remaining business or take time to complete, while some view the listing as a way to unlock Monees value.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs steep selloff is being debated amid broader fears about neocloud financing and Gartners warning that many independent AI infrastructure providers could consolidate. Bullish traders point to CEO Daniel Roberts comments that IRENs data centers carry no debt and customer prepayments help fund GPU costs, while bears remain focused on weak price action and execution risks.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs quarterly earnings beat and higher full-year guidance have been overshadowed by a sharp share-price decline, with traders focusing on rising costs, weaker cash flow, and an insurance-business loss. The community is split between seeing strong orders and services demand as evidence of durable momentum and questioning whether that demand will translate into better margins and cash generation.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTXs quarterly earnings beat, raised full-year outlook and record backlogsupported by long-term missile contracts and strong defense demandare driving attention. Traders welcome the results and demand outlook, but many are frustrated that the share price has stayed weak or turned red despite the positive news.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Unconfirmed Iran-U.S. deal chatter and a pullback in oil dominated discussion, with traders linking the headlines to a sharp QQQ rebound and volatile reversals. Bulls framed the move as a relief rally, while skeptics questioned the reports and warned of a bull trap; tech earnings and AI-sector weakness added uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Indian companies invest USD 20.5 billion in US, pharma tops

… Embassy & Consulates in India. The pharmaceutical sector accounted for the vast majority … ;s Laboratories Ltd, Glenmark Pharmaceuticals Ltd, Granules India Ltd, Jubilant … Group, Lupin Limited, Piramal Pharma Ltd., and Zydus Lifesciences Limited …

Brief India: Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums and more

In this briefing: Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums Primer: Anthem Biosciences (1234D IN) - Apr 2026 Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins 1. Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums Sharda Cropchem is an asset-light agrochemical supplier that sources products mainly from China and India, sells globally, and builds competitive advantage through extensive regulatory product registrations instead of manufacturing capabilities. They invest heavily in product registrations, creating large pipeline that converts into revenue over time, driving strong cash flows funding growth internally, and supporting dividends despite high accounting amortization charges. Sharda’s massive registration pipeline and presence in regulated markets drive growth despite sourcing and forex risks.

Brief India: Primer: Anthem Biosciences (1234D IN) - Apr 2026 and more

In this briefing: Primer: Anthem Biosciences (1234D IN) - Apr 2026 Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan 1. Primer: Anthem Biosciences (1234D IN) - Apr 2026 Anthem Biosciences is a fully integrated Contract Research, Development, and Manufacturing Organization (CRDMO) providing end-to-end services for small and large molecules to the global pharmaceutical and biotechnology sectors. The company has demonstrated a strong financial track record, with a 32% CAGR in operating revenue between FY23 and FY25, and boasts industry-leading EBITDA margins. Key growth drivers include its leadership in fermentation capacity in India, expertise in advanced therapeutic modalities like ADCs and RNAi, and a strategic focus on backward integration to reduce reliance on external suppliers.

Brief India: Amagi Media Labs: Taking Media Companies to the Cloud Universe and more

In this briefing: Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan The Adani Group Clearance: Deconstructing the CCI Verdict and What It Means for the Conglomerate 1. Amagi Media Labs: Taking Media Companies to the Cloud Universe Amagi's unified cloud-based media infrastructure serves to digitise traditional media content and enable monetisation. Its two-way platform supports not just the content-owners but also distributors globally with varied content access By attracting both media companies and distributors, Amagi benefits from a content-driven flywheel effect, creating structural stickiness with 120+% NRR and 35–50% cost savings for broadcasters. Amagi has been a key enabler for broadcasting for live-events (FIFA, NFL) while its content library attracts small/new OTT platforms.

Brief Multi-Strategy: Approaches Aimed at Resolving “parent-Subsidiary Listings” in the Broad Sense Remain Effective and more

In this briefing: Approaches Aimed at Resolving “parent-Subsidiary Listings” in the Broad Sense Remain Effective Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) HEW: Rallying into the Void Japan Strategy Weekly Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins 1. Approaches Aimed at Resolving “parent-Subsidiary Listings” in the Broad Sense Remain Effective A common challenge faced by Japanese companies is inability to concentrate resources on businesses with high profit margins and growth potential, resulting in failure to successfully expand promising businesses overseas. Establishing and implementing clear criteria for deciding when to invest in or withdraw from businesses is essential for restructuring the business portfolio. The litmus test is eliminating parent-subsidiary dual listings. The Standard Market is likely to become the main battleground for efforts to resolve parent-subsidiary dual listings.In the Prime Market, increased approaches from activist investors targeting equity-method affiliates are inevitable. 2.

Brief Multi-Strategy: Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) and more

In this briefing: Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) HEW: Rallying into the Void Japan Strategy Weekly Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins The Stocks to Own in China – Vol. 39 1. Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Downstream oil products remain elevated, yet oil futures continue to soften. GCC states say that it will take years to rebuild and replace some infrastructure. The petrodollar has taken a hit as Gulf countries are selling less oil and emerging markets are forced to sell dollars to plug deficits caused by higher oil prices. The petroyuan is gaining traction as the Middle East conflict has rerouted some payments through the Chinese CIPS and mBridge networks. 2. HEW: Rallying into the Void No news was good enough news for risk assets to keep rallying, but even a benign end to the US-Iran war will not negate the inflation shock lifting policy rates. EA inflation recovered some of its downside surprise in its final March print, but the UK’s international stature can’t recover.

Brief India: Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) and more

In this briefing: Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan The Adani Group Clearance: Deconstructing the CCI Verdict and What It Means for the Conglomerate Primer: Cipla Ltd (CIPLA IN) - Apr 2026 1. Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Downstream oil products remain elevated, yet oil futures continue to soften. GCC states say that it will take years to rebuild and replace some infrastructure. The petrodollar has taken a hit as Gulf countries are selling less oil and emerging markets are forced to sell dollars to plug deficits caused by higher oil prices. The petroyuan is gaining traction as the Middle East conflict has rerouted some payments through the Chinese CIPS and mBridge networks. 2. Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins US Paracetamol prices jumped 24.6% MoM in March 2026 , driven by post-Lunar New Year Chinese supply pullback, Indian facility FDA alerts & surging para-aminophenol cost.

Brief Multi-Strategy: HEW: Rallying into the Void and more

In this briefing: HEW: Rallying into the Void Japan Strategy Weekly Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins The Stocks to Own in China – Vol. 39 CX Daily: ByteDance’s Billion-Yuan Bet on China’s First AI-Native Hospital? 1. HEW: Rallying into the Void No news was good enough news for risk assets to keep rallying, but even a benign end to the US-Iran war will not negate the inflation shock lifting policy rates. EA inflation recovered some of its downside surprise in its final March print, but the UK’s international stature can’t recover. It failed to defend its investing allies. Next week is packed with news for the UK, where the rise in its inflation data is our highlight, with its labour market and global flash PMIs other notable releases. 2. Japan Strategy Weekly Japanese equities posted a modest gain this week, with the Topix Index rising +0.6% and extending its year-to-date advance to +10.3%. The move came against a supportive global backdrop, as U.S. markets rallied strongly— Nasdaq climbed ~4%—helping sustain risk appetite despite pockets of volatility.

Brief Multi-Strategy: Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins and more

In this briefing: Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins The Stocks to Own in China – Vol. 39 CX Daily: ByteDance’s Billion-Yuan Bet on China’s First AI-Native Hospital? The Adani Group Clearance: Deconstructing the CCI Verdict and What It Means for the Conglomerate Samsung Electronics - Pays Out Special Dividend & Consensus Likely to Raise DPS by 30%+ for 2026 1. Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins US Paracetamol prices jumped 24.6% MoM in March 2026 , driven by post-Lunar New Year Chinese supply pullback, Indian facility FDA alerts & surging para-aminophenol cost. Indian API-heavy players like Granules India, Aurobindo, Dr. Reddy's & IPCA face squeeze of input costs & restricted supply of exports , compressing EBITDA when the US pharma tariff threat looms. Integrated giants like Sun Pharma & Cipla have buffers; pure-play API and formulation players like Granules India are most exposed. This situation is worth tracking closely heading into FY26 earnings. 2.

Brief India: Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins and more

In this briefing: Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan The Adani Group Clearance: Deconstructing the CCI Verdict and What It Means for the Conglomerate Primer: Cipla Ltd (CIPLA IN) - Apr 2026 Primer: Indus Towers (INDUSTOW IN) - Apr 2026 1. Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins US Paracetamol prices jumped 24.6% MoM in March 2026 , driven by post-Lunar New Year Chinese supply pullback, Indian facility FDA alerts & surging para-aminophenol cost. Indian API-heavy players like Granules India, Aurobindo, Dr. Reddy's & IPCA face squeeze of input costs & restricted supply of exports , compressing EBITDA when the US pharma tariff threat looms. Integrated giants like Sun Pharma & Cipla have buffers; pure-play API and formulation players like Granules India are most exposed. This situation is worth tracking closely heading into FY26 earnings. 2. Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan Gold loans have overtaken home loans by origination value, reaching ~39% of retail disbursals as of December 2025, with the portfolio growing 4x since March 2022 to ~INR3.38 lakh crore.

Granules India Ltd. engages in the manufacturing and marketing of pharmaceutical products. It operates through the following business segments: Active Pharmaceutical Ingredient, Pharmaceutical Formulation Intermediates, and Finished Dosages. The company was founded by Krishna Prasad Chigurupati on March 18, 1991 and is headquartered in Hyderabad, India.

Granules India Ltd.

Granules India Shares: Technical Charts Hint At Trend Reversal, Says SEBI RA Deepak Pal

Equity

Neutral Sentiment

Granules India shares have fallen 7% over the last month; however, their technical charts are indicating a short-term trend reversal.&nbsp;SEBI-registered&nbsp;<a href="https://stocktwits.com/Investogainerresearch">analyst Deepak Pal</a>+ noted that on its daily chart, the stock had been trading below its 14 &amp; 55-day Exponential Moving Average (EMA) since June 24th, indicating short-term weakness.&nbsp;&nbsp;<a href="https://stocktwits.com/symbol/GRANULES.NSE">Granules India stock</a> is facing consistent resistance at its 55-day EMA on the daily chart and around its 14-day EMA on the weekly chart. However, he noted that the stock was taking strong support near the ₹475 level.&nbsp;On June 19th and 20th, the stock hit lows of around ₹479 and subsequently witnessed a reversal. Even on Thursday, the stock traded in a narrow range, opening at ₹492, making a high of ₹495, a low of ₹487.45, and closing at ₹490.15.&nbsp;&nbsp;On the daily chart, Pal flagged that a triangle pattern is forming, and both technical indicators –&nbsp;Moving Average Convergence Divergence (MACD)&nbsp;and Relative Strength Index (RSI) – are indicating a short-term positive trend.&nbsp;He suggested that traders can consider fresh entries with the stock trading near ₹490, with a stop loss of ₹475. If the stock sustains this support and breaks above the resistance zone, it could quickly move towards ₹525 levels in the near term.<stembedurl>https://stocktwits.com/Investogainerresearch/message/619891533</stembedurl>Fundamentally, Granules India holds a dominant position in key products such as Paracetamol and Ibuprofen, and is steadily expanding its portfolio of high-margin, complex generics. The company’s regulatory approvals position it well for future growth, and improving debt profile highlights its financial strength.&nbsp;Despite near-term challenges, it remains a fundamentally sound player in the Indian pharmaceutical sector, with promising long-term growth potential, he concluded.Data on Stocktwits shows that retail sentiment is ‘bullish’ on this counter.<figure class="image"><img style="aspect-ratio:806/104;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_04_121118_png_5bc69c3e00.webp" alt="Screenshot 2025-07-04 121118.png" width="806" height="104"><figcaption>Granules sentiment and message volume on July 4 as of 12:30 pm IST. | source: Stocktwits</figcaption></figure>Granules India shares have fallen 17% year-to-date (YTD).For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Technical indicators, such as MACD and RSI, are turning positive. The analyst suggests potential upside to ₹525.

Current Price	802.85
Prev Close	823.00
Open	818.90
Dividend Yield	0.28%
50-Day Moving Average	853.61
Beta	-0.02
Avg. Volume	1.48M
PE Ratio	29.78

52-Week High	985.00
52-Week Low	529.85
Market Capitalization	199.87B
EPS (Annual)	24.47
Price to Book	3.93
Revenue Per Employee	8.23M

Feed

News

Sentiment

Fundamentals

Info

GRANULES.NSE Fundamentals